25

2025y11m

Belief BioMed Announces IND Clearance by NMPA for Cervix High-grade Squamous Intraepithelial Lesion Gene Therapy Candidate BBM-C101

​Shanghai, China, November 25, 2025 —— Belief BioMed (BBM), an innovative biotechnology company focused on developing cutting-edge gene therapies, today announced that it has received National Medical Products Administration (NMPA) clearance of ...

20

2025y11m

BBM-H901 Makes Another Appearance in an Authoritative International Journal! Nature Medicine Published Latest Data on BBM-H901 for Hemophilia B

​Shanghai, China, November 20, 2025 — Belief BioMed (BBM), an innovative biotechnology company focused on developing cutting-edge gene therapies, today announced that the data from the Phase 1/2 and Phase 3 (NCT05203679) clinical ...

14

2025y05m

Belief BioMed Announces Implied Clinical Trial Approval by NMPA for Parkinson's Disease Gene Therapy Candidate BBM-P002

Shanghai, China, May 14th, 2025 —— Belief BioMed (BBM), an innovative biotechnology company focused on developing cutting-edge gene therapies, today announced that it has received National Medical Products Administration (NMPA) implied approval of an Inv…

18

2025y04m

Belief BioMed Announces IND Clearance by NMPA for Duchenne Muscular Dystrophy Gene Therapy Candidate BBM-D101

Shanghai, China, April 18th, 2025 —— Belief BioMed (BBM), an innovative biotechnology company focused on developing cutting-edge gene therapies, today announced that it has received National Medical Products Administration (NMPA) clearance of an Investig…

10

2025y04m

Belief BioMed and Takeda China jointly announced BBM-H901 (Dalnacogene Ponparvovec Injection), China’s first hemophilia B gene therapy, was officially approved

Shanghai, China, April 10 2025 – Belief BioMed ("BBM") and Takeda China today jointly announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the National Medical Products Administration (NMPA)

27

2025y03m

Belief BioMed Announces IND Clearance by NMPA for Osteoarthritis Gene Therapy Candidate BBM-A101 Injection

Shanghai, China, March 27th, 2025 —— Belief BioMed (BBM), an innovative biotechnology company focused on developing cutting-edge gene therapies, today announced that it has received National Medical Products Administration (NMPA) clearance of an Investig…

05

2025y02m

Belief BioMed Announces IND Acceptance by NMPA for Duchenne Muscular Dystrophy Gene Therapy Candidate BBM-D101

Shanghai, China, February 5th, 2025 —— Belief BioMed (BBM), an innovative biotechnology company focused on developing cutting-edge gene therapies, today announced that it has received National Medical Products Administration (NMPA) acceptance of an Inves…

25

2025y01m

Belief BioMed Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate BBM-D101

Shanghai, China, January 22th, 2025 —— Belief BioMed (BBM), an innovative biotechnology company focused on developing cutting-edge gene therapies, today announced that it has received U.S. Food and Drug Administration (FDA) clearance of an Investigationa…

06

2024y11m

Belief BioMed's Gene Therapy for DMD Receives Orphan Drug Designation & Rare Pediatric Disease Designation from the U.S. FDA

Shanghai, China, November 06, 2024 — Belief BioMed Inc. (hereinafter, "BBM"), a globally innovative biotech company focusing on cutting-edge gene therapies, announced today that the U.S. Food and Drug Administration (FDA) has recently granted Or

25

2024y10m

Great news! The gene therapy for hemophilia B developed by Belief BioMed has received Advanced Therapy Medicinal Product Designation from the EMA!

Shanghai, China, September 25, 2024 — Belief BioMed Inc. (BBM), a biotech company focusing on innovative gene therapies, today announced a new strategic collaboration with Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and